<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Amyloid imaging with (18)F-labeled radiotracers will allow widespread use, facilitating research, diagnosis, and therapeutic development for <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of the study program was to compare cortical <z:mpath ids='MPATH_34'>amyloid deposition</z:mpath> using (18)F-florbetaben and PET in controls and subjects with mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (MCI), <z:e sem="disease" ids="C0751072" disease_type="Mental or Behavioral Dysfunction" abbrv="FTLD">frontotemporal lobar degeneration</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>), <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>), vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD), <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>), and <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> (AD) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: One hundred nine subjects in 3 clinical studies at Austin Health were reviewed: 32 controls, 20 subjects with MCI, and 30 patients with AD, 11 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>, 7 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, 5 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>, and 4 with VaD underwent PET after intravenous injection of 300 MBq of (18)F-florbetaben </plain></SENT>
<SENT sid="3" pm="."><plain>Standardized uptake value ratios (SUVR) using the cerebellar cortex as a reference region were calculated between 90 and 110 min after injection </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: When compared with the other groups, AD patients demonstrated significantly higher SUVRs (P &lt; 0.0001) in neocortical areas </plain></SENT>
<SENT sid="5" pm="."><plain>Most AD patients (96%) and 60% of MCI subjects showed diffuse cortical (18)F-florbetaben retention </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, only 9% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>, 25% of VaD, 29% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, and no <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> patients and 16% of controls showed cortical binding </plain></SENT>
<SENT sid="7" pm="."><plain>Although there was a correlation between Mini Mental State Examination and Î²-amyloid burden in the MCI group, no correlation was observed in controls, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e> or AD </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: (18)F-florbetaben had high sensitivity for AD, clearly distinguished patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e> from AD, and provided results comparable to those reported with (11)C-Pittsburgh Compound B in a variety of <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> </plain></SENT>
</text></document>